» Articles » PMID: 29557391

Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells

Overview
Journal Med Sci Monit
Date 2018 Mar 21
PMID 29557391
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Cyclin Y (CCNY) is a member of the cyclin family of proteins that regulate the cell cycle. The aims of this study were to compare the expression of CCNY in normal liver and human hepatocellular carcinoma (HCC), in normal and HCC cell lines, and in mouse HCC tumor xenografts. MATERIAL AND METHODS Tumor tissues from 55 patients diagnosed with HCC were studied for CCNY expression. Human HCC cell lines, SK-Hep1, HepG2, HEP3B, HuH7 and L02 were studied using the MTT cell proliferation assay, cell apoptosis, transwell and wound healing assays. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot were used to measure CCNY expression. Indirect immunofluorescence was used to assess cell apoptosis. In vivo xenograft mouse model was constructed and examined histologically. RESULTS Expression of CCNY in human HCC tumor tissues was significantly increased when compared with adjacent normal liver (all P<0.05). HCC cells grown in vitro showed significantly increased expression of CCNY, cell proliferation, and migration, and a reduced rate of apoptosis, compared with cells with CCNY knockdown (siRNA) (all P<0.05). In the xenograft mouse model, tumor volume and weight in the CCNY overexpression group were significantly increased, compared with CCNY knockdown (siRNA) group (all P<0.05). CONCLUSIONS In tissue samples of human HCC, and human HCC cell lines, increased expression of CCNY was significantly associated with cell proliferation and migration. Further studies are recommended to evaluate the role of CCNY as a potential diagnostic biomarker or target for treatment in human HCC.

Citing Articles

LncRNA MEG3, GAS5, and HOTTIP Polymorphisms Association with Risk of Polycystic Ovary Syndrome: A Case-Control Study and Computational Analyses.

Majidpour M, Sargazi S, Ghasemi M, Akbar-Abad M, Sarhadi M, Saravani R Biochem Genet. 2024; .

PMID: 39613922 DOI: 10.1007/s10528-024-10977-1.


TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.

Bitter E, Skidmore J, Allen C, Erickson R, Morris R, Mortimer T PLoS One. 2023; 18(11):e0293128.

PMID: 38033034 PMC: 10688958. DOI: 10.1371/journal.pone.0293128.


Research Advances in the Role of the Tropomyosin Family in Cancer.

Meng Y, Huang K, Shi M, Huo Y, Han L, Liu B Int J Mol Sci. 2023; 24(17).

PMID: 37686101 PMC: 10488083. DOI: 10.3390/ijms241713295.


Disturbing cytoskeleton by engineered nanomaterials for enhanced cancer therapeutics.

Xu X, Xu S, Wan J, Wang D, Pang X, Gao Y Bioact Mater. 2023; 29:50-71.

PMID: 37621771 PMC: 10444958. DOI: 10.1016/j.bioactmat.2023.06.016.


The role of cyclin Y in normal and pathological cells.

Opacka A, Zuryn A, Krajewski A, Mikolajczyk K Cell Cycle. 2022; 22(8):859-869.

PMID: 36576166 PMC: 10054165. DOI: 10.1080/15384101.2022.2162668.


References
1.
Mikolcevic P, Sigl R, Rauch V, Hess M, Pfaller K, Barisic M . Cyclin-dependent kinase 16/PCTAIRE kinase 1 is activated by cyclin Y and is essential for spermatogenesis. Mol Cell Biol. 2011; 32(4):868-79. PMC: 3272973. DOI: 10.1128/MCB.06261-11. View

2.
Trepo C, Chan H, Lok A . Hepatitis B virus infection. Lancet. 2014; 384(9959):2053-63. DOI: 10.1016/S0140-6736(14)60220-8. View

3.
Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A . Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol. 2015; 7(16):2020-8. PMC: 4528275. DOI: 10.4254/wjh.v7.i16.2020. View

4.
Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

5.
Guimaraes E, de Carli M, Sperandio F, Hanemann J, Pereira A . Cyclin D1 and Ki-67 expression correlates to tumor staging in tongue squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2015; 20(6):e657-63. PMC: 4670244. DOI: 10.4317/medoral.20601. View